2014
DOI: 10.1172/jci72517
|View full text |Cite
|
Sign up to set email alerts
|

Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
169
0
4

Year Published

2016
2016
2024
2024

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 241 publications
(180 citation statements)
references
References 76 publications
0
169
0
4
Order By: Relevance
“…If the probiotics are shown to be effective as they have been in initial studies [21], they should be used in place of the current medications when possible. Probiotics are healthy bacteria that are a part of the human digestive tract; using them to treat gastrointestinal disorders and help return the gut to a state of homeostasis is preferable to introducing medications that will further eradicate the healthy gut bacteria and increase the risk of more serious gastrointestinal distress [30][31][32]. As Horveth discusses, individual strains need to be tested first and then probiotic combination therapies to develop effective probiotics to treat gastrointestinal disorders [21].…”
Section: Discussionmentioning
confidence: 99%
“…If the probiotics are shown to be effective as they have been in initial studies [21], they should be used in place of the current medications when possible. Probiotics are healthy bacteria that are a part of the human digestive tract; using them to treat gastrointestinal disorders and help return the gut to a state of homeostasis is preferable to introducing medications that will further eradicate the healthy gut bacteria and increase the risk of more serious gastrointestinal distress [30][31][32]. As Horveth discusses, individual strains need to be tested first and then probiotic combination therapies to develop effective probiotics to treat gastrointestinal disorders [21].…”
Section: Discussionmentioning
confidence: 99%
“…Engineering of a different probiotic chassis, EcN, has also produced relevant strains with therapeutic effects against IBDs (Whelan et al ., 2014) and against obesity (Chen et al ., 2014). The company Synlogic (http://www.synlogictx.com/) is engineering EcN as a microbial chassis for development of human therapeutics (Synthetic Biotic™) against IBDs, cancer and metabolic deficiencies, such as urea cycle disorder and phenylketonuria (http://www.synlogictx.com/pipeline/pipeline/).…”
Section: Engineered Bacteria Against Immunological and Metabolic Disementioning
confidence: 99%
“…A modifi kált baktériumokat kapó egerekben szignifi kánsan csökkent a táplálékfelvétel, az elhízás mértéke, az inzulinrezisztencia és a hepatosteatosis a kontrollegerekhez képest. A modifi kált baktériumok inkorporációja a bélmikrobiótába eredményesen gátolta a metabolikus elváltozások kialakulását [55]. Sovány férfi donorból metabolikus szindrómás férfi be történő fekális transzplantáció (FMT) szignifi kánsan javította az inzulinérzékenységet és megnövelte a mikrobiális diverzitást, ezen belül a butiráttermelő törzsek szaporodását.…”
Section: Széklettranszplantációunclassified